Q2 2026 Amphastar Pharmaceuticals, Inc Earnings Call Transcript

Aug 6, 2026 / 09:00 PM GMT

Release Date Price: €17.06 (-1.56%)

Transcript 10-Q8-K

Key Points

Positve

Amphastar Pharmaceuticals Inc (AMPH) reported a 5% year-over-year revenue increase to $183.9 million, driven by strong sales of recently launched products like ipratropium bromide ($8.4 million), teriparatide ($4.5 million), and iron sucrose ($3.5 million).
The company achieved the first annual Vascepa net sales milestone of $178.3 million, triggering a $100 million payment from Eli Lilly, demonstrating successful execution of its commercial strategy for the franchise.
Vascepa prescription volume grew approximately 17% year-over-year, indicating strong underlying patient demand despite a slight revenue decline due to pricing dynamics.
Gross margins improved to 51% of revenues in Q2 2026, up from 50% in the prior year period, driven by a favorable product mix from higher-margin recently launched products.
The company maintained its overall corporate sales guidance of mid-single-digit to high-single-digit growth for 2026, reflecting confidence in the strength of its diversified portfolio despite headwinds.
Amphastar Pharmaceuticals Inc (AMPH) generated strong cash flow from operations of approximately $51.3 million in Q2 and accelerated its share repurchase program, buying back about $45 million worth of shares.

Negative

Amphastar Pharmaceuticals Inc (AMPH)'s IMS subsidiary received an FDA warning letter related to a December 2025 inspection, leading to increased remediation expenses of $2-3 million per quarter and a slight slowing of sales from the facility.
Vascepa net sales decreased 3% year-over-year to $45.5 million due to lower average selling prices, higher rebates, and increased 340B pharmacy discounts, some of which were duplicated.
Glucagon sales declined 42% year-over-year to $11.9 million due to increased competition, and management does not expect this product to return to growth, only a more muted decline.
Primatene Mist reported net sales declined due to consumer ordering patterns and timing of shipments associated with pricing discussions with certain retailers, creating temporary channel-related effects.
Selling, distribution, and marketing expenses increased 30% year-over-year, and general and administrative expenses also rose 30%, driven by higher legal expenses, personnel costs, and ERP system implementation costs.
The company expects R&D expenses to tick up as a percentage of sales going forward, primarily due to increased clinical trial expenses for its insulin pipeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMPH.OQ - Amphastar Pharmaceuticals, Inc.
Q2 2026 Amphastar Pharmaceuticals, Inc Earnings Call
Aug 06, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Amphastar Pharmaceuticals Inc.

Second quarter earnings call.

At this time, all participants are in a listen-only mode.

A question-and-answer session will follow a formal presentation.

If anyone should require further assistance during this conference, please press 0 on your telephone keypad.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods are forward-looking statements.

These statements are based solely on information that is now available to us.

We encourage you to review the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.